Information Provided By: 
Fly News Breaks for January 23, 2020
KRTX
Jan 23, 2020 | 10:24 EDT
William Blair analyst Myles Minter maintained an Outperform rating with a $105 fair value estimate for Karuna Therapeutics (KRTX) following the company's $200M equity sale to Goldman Sachs. The analyst said that while the sale was discounted, and has taken the stock price down about 20% in pre-market trading, it does not alter his "fundamental view that Karuna holds the first truly novel antipsychotic in over 30 years in KarXT," and he would be a buyer on weakness.
News For KRTX From the Last 2 Days
KRTX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
